Anagrelide

Another Name
Agrylin Anagrelide Anagrelide hydrochloride Thrombocytopenic agents,阿那格雷
Indications
Treat essential thrombocythemia (ET)
Reg No
08 L 1180/24
Inspection No
2012-24
dosage form:Capsules
Specs:0.5mg*100 Capsules
Indate:2 Years
Date:2024-10-18 Views:1200

COMPOSITION:

Each capsule contains Anagrelide hydrochloride 0.607 mg equivalentto Anagrelide…………0.5mg.

INDICATION:

Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events.

DOSAGE AND USE:

• The starting dose for adults is 0.5 mg four times a day or 1 mg twice a day.

• The starting dose for pediatric patients is 0.5 mg per day.

• Maintain the starting dose for at least one week and then titrate to maintain target platelet counts.

• Do not exceed a dose increment of 0.5 mg/day in any one week. Do not exceed 10 mg/day or 2.5 mg in a single dose.

• Moderate hepatic impairment: Start with 0.5 mg per day.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciAnagre during Pregnancy and Lactation.

Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/anagrelide/

Related News